We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Nov 2022
  • Code : CMI936
  • Industry : Biotechnology
  • Pages : 184
  • Formats :

Platelet-rich  plasma (PRP), also called platelet enriched plasma or platelet gel, is a blood plasma product, which contains elevated level of platelets and growth factors (at least four to ten times) than normal blood concentration. An increased blood plasma concentration accentuates the injury healing process by releasing high amount of growth factors at the injury site. Some of the main benefits of injecting PRP are that they may reduce the need for anti-inflammatory drugs or more potent drugs such as opioids.

Global platelet rich plasma market is estimated to be valued at US$ 442.7 million in 2022 and is expected to exhibit a CAGR of 12.4% during the forecast period (2022-2030).

Figure 1.Global Platelet Rich Plasma Market Share (%), by Application, 2022

Platelet Rich Plasma  | Coherent Market Insights

Global Platelet Rich Plasma Market- Drivers

Increase in number of cosmetic surgeries is expected to propel growth of the global platelet rich plasma market over the forecast period. For instance, according to a survey of International Society of Aesthetic Plastic Surgery (ISAPS), 2020 approximately 10,129,528 surgical procedures such as eyelid surgery, ear surgery and Liposuction were performed worldwide and 14,400,347 non- surgical procedures such as hair removal, photo rejuvenation and botulinum toxin were performed.

Moreover, high prevalence of sports injuries is also expected to aid in growth of the global platelet rich plasma market over the forecast period. For instance, according to the National High School Sports-Related Injury Surveillance Study 2021-2022, 1,385,717 cases of sport-related injuries were recorded in high schools in the U.S.

CMI table icon

Platelet Rich Plasma Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 442.7 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 12.4% 2030 Value Projection: US$ 1,129.4 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: Pure PRP, Leukocyte rich PRP, Pure PRF, Leukocyte rich PRF
  • By Origin: Autologous, Allogenic, Homologues
  • By Application: Neurosurgery, Cosmetic Surgery, Orthopedic Surgery, General Surgery, Others
Companies covered:

Arthrex, Inc., Stryker Corporation, Johnson and Johnsons Ltd., Zimmer Biomet Holdings Inc., Terumo Corporation, Glofinn Oy, Medira Ltd., Regen Lab S.A., CollPlant, Generex Biotechnology Corporation, Estar Technologies Ltd., Dr. PRP America, Cesca Therapeutics, Inc., Arteriocyte Medical Systems, Harvest Technologies Corp.

Growth Drivers:
  • Increase in number cosmetic surgeries
  • High prevalence of sports injuries
Restraints & Challenges:
  • High cost of platelet rich plasma products

Figure 2.Global Platelet Rich Plasma Market Share (%), by Region, 2022

Platelet Rich Plasma  | Coherent Market Insights

Global Platelet Rich Plasma Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another.

However, the COVID-19 pandemic had a positive impact on the global platelet rich plasma market. For instance, on August 1, 2021 a phase 3 clinical trial sponsored by Centre Hospitalar Universities Saint Pierre, results showed that Olfactory dysfunction (OD) is a well know symptom of coronavirus disease that platelet rich plasma in the olfactory cleft increases the olfactory threshold one month after injection and platelet rich plasma is a safe treatment because no adverse effects were found.

Global Platelet Rich Plasma Market: Key Developments

High prevalence of alopecia is expected to boost growth of the global platelet rich plasma market. For instance, on September 2, 2022, figures from Scandinavian Biolabs states that 95% of male hair loss is caused by androgenetic alopecia, and one in four men will begin to bald before the age of 21. The use of autologous platelet-rich plasma (PRP) has become a common procedure in cosmetic surgery and dermatology to improve hair growth and thickness in patients with androgenetic alopecia.

Increasing and evolving role of platelet rich plasma in plastic surgeries is expected to boost the global platelet rich plasma over the forecast period. For instance, on December 23, 2020, a press release produced by American Society of Plastic Surgeons, stated that treatments using platelet rich plasma show great improvement for harnessing body’s own natural tissue repair process.

Global Platelet Rich Plasma Market: Restraint

High cost of platelet rich plasma products is also expected to hinder growth of the market. The average price of platelet rich plasma injections starts from US$ 200 to US$ 800, based on its application areas. In addition, treatment of chronic diseases/injuries requires minimum three to six injections, which increases the overall cost of the treatment. Similarly, according to Coastal Orthopedics platelet rich plasma therapy for muscle or tendon injury will cost US$1400 (US$700 per injection).

Global Platelet Rich Plasma Market- Key Players

Major players operating in the global platelet rich plasma market include Arthrex, Inc., Stryker Corporation, Johnson and Johnsons Ltd., Zimmer Biomet Holdings Inc., Terumo Corporation, Glofinn Oy, Medira Ltd., Regen Lab S.A., CollPlant, Generex Biotechnology Corporation, Estar Technologies Ltd., Dr. PRP America, Cesca Therapeutics, Inc., Arteriocyte Medical Systems, Harvest Technologies Corp.

Platelet rich plasma (PRP) is a portion of the plasma fraction of analogous blood, which contains platelet concentration more than standard concentration. Platelets contains bio proteins that helps in healing, tissue regeneration, and blood loss. Platelet rich plasma protein consists of three proteins, which acts as cell adhesive molecules that are fibrin, fibronectin, and vitronectin. PRP therapy can improve joint and trauma-related wound healing. The surgery can improve other aesthetic surgeries, treat male pattern baldness, and encourage the growth of hair transplants.

To promote the repair of injured tendons, ligaments, muscles, and joints, platelet-rich plasma (PRP) therapy involves injections of a patient's own concentrated platelets. PRP injections work to treat musculoskeletal issues by enhancing each patient's natural healing process. One to several tubes of your own blood are used to prepare PRP injections, which is done by centrifuging the blood to concentrate the platelets. The damaged or ill body tissue is subsequently given an injection of these activated platelets. This causes the release of growth factors, which promote and boost your body's production of reparative cells.

Market Dynamics

Evolving role of platelet rich plasma in plastic surgeries for facial rejuvenation and hair restoration is expected to drive the global platelet rich plasma market over the forecast period. For instance, on January 1, 2021, an article published in national library of medicine stated that there is a strong proof using unbiased measurement techniques that shows successful treatment results for skin rejuvenation, hair development, wound healing, and fat graft take. There is a therapeutic benefit to using plasma rich in platelets as a unique treatment method for alopecia and skin rejuvenation.

Key features of the study:

  • This report provides in-depth analysis of the global platelet rich plasma market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global platelet rich plasma market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Arthrex, Inc., Stryker Corporation, Johnson and Johnsons Ltd., Zimmer Biomet Holdings Inc., Terumo Corporation, Glofinn Oy, Medira Ltd., Regen Lab S.A., CollPlant, Generex Biotechnology Corporation, Estar Technologies Ltd., Dr. PRP America, Cesca Therapeutics, Inc., Arteriocyte Medical Systems, Harvest Technologies Corp.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global platelet rich plasma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global platelet rich plasma market

Detailed Segmentation:

  • Global Platelet Rich Plasma Market, By Type:
    • Pure PRP
    • Leukocyte rich PRP
    • Pure PRF
    • Leukocyte rich PRF
  • Global Platelet Rich Plasma Market, By Origin:
    • Autologous
    • Allogenic
    • Homologues
  • Global Platelet Rich Plasma Market, By Application:
    • Neurosurgery
    • Cosmetic Surgery
    • Orthopedic Surgery
    • General Surgery
    • Others
  • Global Platelet Rich Plasma Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Arthrex, Inc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Stryker Corporation
    • Johnson and Johnsons Ltd.
    • Zimmer Biomet Holdings Inc.
    • Terumo Corporation
    • Glofinn Oy
    • Medira Ltd.
    • Regen Lab S.A.
    • CollPlant
    • Generex Biotechnology Corporation
    • Estar Technologies Ltd.
    • PRP America
    • Cesca Therapeutics, Inc.
    • Arteriocyte Medical Systems
    • Harvest Technologies Corp.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global platelet rich plasma market size is estimated to be valued at US$ 442.7 million in 2022 and is expected to exhibit a CAGR of 12.4% between 2022 and 2030.
Factors such as increase in cosmetic surgery and high prevalence of sport related injuries are the major factors driving the market.
Orthopedic surgery is the leading application segment in the market.
The major factors hampering growth of the market include high cost of platelet rich plasma products.
Major players operating in the market include Arthrex, Inc., Stryker Corporation, Johnson and Johnsons Ltd., Zimmer Biomet Holdings Inc., Terumo Corporation, Glofinn Oy, Medira Ltd., Regen Lab S.A., CollPlant, Generex Biotechnology Corporation, Estar Technologies Ltd., Dr. PRP America, Cesca Therapeutics, Inc., Arteriocyte Medical Systems, Harvest Technologies Corp.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo